Before you Buy: Check the Credit Tab to Make Sure Your Jurisdiction is Accredited!
Located in the center of Europe and without being a member of the European Union, Switzerland is home to Europe’s most progressive cannabis laws. Cannabis with a THC content below 1 pct is not considered a narcotic drug, which led to the development of one of the most active and mature CBD markets in the world. Most recently, Switzerland passed regulations which allow for the initiation of pilot schemes wherein adult-use cannabis can be legally produced and distributed to registered users, which will make Switzerland, next to the Netherlands, the first region in Europe to allow for a fully legalized adult-use cannabis supply chain. The Swiss Parliament further adopted a proposed amendment to the Narcotics Act which shall facilitate patient’s access to medicinal cannabis, and provide a framework for exports. This one hour session will touch on the legal framework of recreational and medicinal cannabis in Switzerland and provide a high-level overview of the newest developments, the challenges, as well as the opportunities in Switzerland’s dynamic cannabis market.
This program is eligible for 1 hours of General CLE credit in 60-minute states, and 1.2 hours of General CLE credit in 50-minute states. Credit hours are estimated and are subject to each state’s approval and credit rounding rules.
INCBA webinars are eligible for credit in the following states: AR, AL, AK, AZ, CA, CO, CT,DE, GA, HI, IL, IN, MN, MS, MO, NV, NH, NJ, NM, NY, NC, ND, OH, OR, PA, TN, TX, UT, VT, WV, and WI . Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted. For many live events, credit approval is not received prior to the program.
INCBA on demand programs are eligible for credit in the following states: AR, AL, AK, AZ, CA, CO, CT,DE, GA, HI, IL, IN, MN, MS, MO, NV, NH, NJ, NM, NY, NC, ND, OH, OR, PA, TN, TX, UT, VT, WV, and WI . Additional states may be available for credit upon self-application by attendees. States typically decide whether a program qualifies for MCLE credit in their jurisdiction 4-8 weeks after the program application is submitted.
For current accreditation status, please select your jurisdiction below.
|Swissmedic CBD implementation guide (265.6 KB)||Available after Purchase|
|Cannabis in Switzerland (6.9 KB)||Available after Purchase|
Kai has been a business and corporate lawyer in Germany for almost 17 years gaining wide range of experiences in the process. He is very familiar with the interconnectivity between national and European regulations, especially in regard to consumer protection, product safety and emerging new cannabis products. He has engaged in advocacy relating to cannabis beginning in early stages of his studies at Philipps University Marburg when the German Supreme Court ruled that small amounts of cannabis should not be criminalized. After medical cannabis was legalized in Germany, Kai started a legal blog (canna-biz.legal) on all the relevant new developments in the emerging cannabis market and became a legal expert especially for CBD products.
He regularly speaks at international cannabis conferences on topics of the German and European legal framework. Lastly, he spoke at the Cannabis Expo in Johannesburg, at the ICBC 2021 in Berlin and at the ICBC and CB Expo 2021 in Zurich on the legal framework for a future recreational cannabis market in Germany. He regularly publishes articles in BusinessCann and German law journals. Kai and his law firm KFN+ advise major CBD and medical cannabis companies, as well as companies interested in the emerging recreational cannabis market.
Kai is also legal advisor to the European Industrial Hemp Association (EIHA), which is working on a Novel Food joint application for different CBD products.
Memberships: German Bar Association (DAV), International Cannabis Bar Association (INCBA, Member of Advisory Board), European Industrial Hemp Association (EIHA), German Hemp Association (DHV), Law Enforcement Against Prohibition (LEAP Germany), Branchenverband Cannabiswirtschaft (BvCW).
Born in Löhne/Westf. in 1972, studied law at the Universities of Marburg, Adelaide (Australia), Cologne, legal expert at the press center of the German Federal Diet, worked for the Berlin District Court, for the Director of Public Prosecution in Berlin, for the Office for the Protection of the Constitution and the Hong Kong Consulate General.
Areas of Law:
Daniel Haymann specializes in corporate and commercial law. Based on his extensive business experience, he has a good feel for new markets and understands the requirements of go-to-market and scale-up strategies. As an interdisciplinary and hands-on advisor, his focus is on investments, venture capital and financing transactions as well as regulatory issues in the healthcare and consumer goods sectors.
He advises investors, start-ups and vertically integrated companies along the value chain, including on regulatory issues relating to THC, CBD and other cannabinoids and psychoactive substances, GMP and GDP standards, food and cosmetics regulations and approval procedures before Swissmedic, the Swiss remedy institute.
Daniel is co-founder and co-chair of the European branch of the International Cannabis Bar Association (INCBA Europe). As a Swiss-Israeli dual citizen, he also focuses on serving clients with connections to Israel and strengthening the relevant business relationships.
Prior to his career as a lawyer, Daniel spent over 10 years in senior positions as a commodity trader for multinational corporations.